Farletuzumab is a humanized monoclonal antibody against folate receptor (FRA). sufferers with gastric cancer (GC) received farletuzumab infusion. Neither DLTs nor grade 3/4 toxicities were reported in all cohorts. Major adverse events, including grade 1/2 infusion related reaction (15 patients, 93.8?%), headache (seven patients, 43.8?%), and nausea and decreased appetite (five patients each, 31.3?%), were… Continue reading Farletuzumab is a humanized monoclonal antibody against folate receptor (FRA). sufferers